State Directory

GLP-1 Providers in Alaska

GLP1Search tracks 75 crawl-qualified GLP-1 provider records across 11 Alaska cities, including clinic, telehealth, med spa, and metabolic-health listings where source data is available.

Provider Records

75

Cities

11

Source-Verified

72

Public Pricing

0

Market Snapshot

Where GLP-1 care is concentrated in Alaska

The Alaska directory is led by Anchorage, Wasilla, Fairbanks. Across the state, 97% of provider records include phone plus address or website coverage, 0% list public pricing, and 96% are marked source-verified.

Data Complete

97%

Pricing Visible

0%

Source Verified

96%

Top Alaska cities for GLP-1 providers

Anchorage AK 48 Wasilla AK 7 Fairbanks AK 4 Soldotna AK 4 Homer AK 3 Palmer AK 3 Ketchikan AK 2 Eagle River AK 1 Girdwood AK 1 Kenai AK 1 Seward AK 1

Featured provider records in Alaska

Alaska Center for Dermatology Anchorage GLP-1 provider Avante Medical Center Anchorage GLP-1 provider Glacier Surgical & Med Spa Palmer GLP-1 provider Borealis Medspa Fairbanks GLP-1 provider Ageless Med Spa Anchorage GLP-1 provider Revive Medical Spa Fairbanks GLP-1 provider Cheeky Medspa - Soldotna (kenai) Kenai GLP-1 provider Adagio Day Spa Anchorage GLP-1 provider Arctic Medical Center & Spa Anchorage GLP-1 provider Fortson Dermatology & Skin Care Center Anchorage GLP-1 provider Aspire Med Spa Anchorage GLP-1 provider Salty Mermaid Beauty Lounge - DOWNTOWN Ketchikan GLP-1 provider

All covered cities in Alaska

Anchorage 48 Eagle River 1 Fairbanks 4 Girdwood 1 Homer 3 Kenai 1 Ketchikan 2 Palmer 3 Seward 1 Soldotna 4 Wasilla 7

Questions about GLP-1 providers in Alaska

How many providers are listed?

GLP1Search lists 75 crawl-qualified GLP-1 provider records across 11 cities in Alaska.

Which cities have the most listings?

Anchorage (48), Wasilla (7), Fairbanks (4), Soldotna (4), Homer (3) currently have the highest listing density in Alaska.

What should patients compare?

Compare licensed clinical oversight, medication source, pharmacy type, public pricing, follow-up cadence, side-effect support, and whether the clinic documents semaglutide or tirzepatide availability.